chloroquine has been researched along with tamoxifen in 47 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.13) | 18.7374 |
1990's | 4 (8.51) | 18.2507 |
2000's | 17 (36.17) | 29.6817 |
2010's | 22 (46.81) | 24.3611 |
2020's | 3 (6.38) | 2.80 |
Authors | Studies |
---|---|
Gochfeld, DJ; Hamann, MT | 1 |
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Alvarez, DE; Boiani, L; Bollini, M; Bruno, AM; Casal, JJ; Cerecetto, H; González, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Sen, S; Sinha, N | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
De Vita, D; Di Santo, R; Maes, L; Matheeussen, A; Moraca, F; Pandolfi, F; Scipione, L; Tortorella, S; Zamperini, C | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Augustyns, K; Baán, A; Caljon, G; Kiekens, F; Maes, L; Matheeussen, A; Salado, IG; Van der Veken, P; Verdeyen, T | 1 |
Amporndanai, K; Antonyuk, S; Berry, NG; Biagini, GA; David Hong, W; Davies, J; Leung, SC; Nixon, GL; O'Neill, PM; Priestley, RS; Samar Hasnain, S; Ward, SA | 1 |
Caljon, G; Courtens, C; Maes, L; Martin, A; Risseeuw, M; Van Calenbergh, S | 1 |
Caljon, G; Cos, P; Courtens, C; Martin, A; Risseeuw, M; Van Calenbergh, S | 1 |
Caljon, G; Cos, P; Courtens, C; Maes, L; Martin, A; Risseeuw, M; Van Calenbergh, S | 1 |
Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
Balde, AM; Baldé, MA; Caljon, G; Cos, P; Foubert, K; Herrebout, W; Matheeussen, A; Peeters, L; Pieters, L; Traoré, MS; Tuenter, E; Vermeyen, T | 1 |
Drenckhahn, D; Jacobi, B; Lüllmann-Rauch, R | 1 |
Kayyali, R; Marriott, C; Wiseman, H | 1 |
Salminen, L; Tähti, H; Toimela, T | 2 |
Balafa, C; Eves, P; Hedley, S; Mac Neil, S; Smith-Thomas, L; Wagner, M | 1 |
Mäenpää, H; Mannerström, M; Salminen, L; Tähti, H; Toimela, T | 1 |
Diehl, H; Engelke, M; Huhtala, A; Mäenpää, H; Mannerström, M; Mäntylä, E; Mäntylä, M; Marselos, M; Pappas, P; Salminen, L; Tähti, H; Toimela, T; Uusitalo, H; Zorn-Kruppa, M | 1 |
Mäenpää, H; Mannerström, M; Salminen, L; Saransaari, P; Tähti, H; Toimela, T | 1 |
Mäenpää, H; Mannerström, M; Saransaari, P; Tähti, H; Toimela, T | 1 |
Toler, SM | 1 |
Beraru, V | 1 |
Amaravadi, RK; Bui, T; Christophorou, MA; Evan, GI; Lum, JJ; Thomas-Tikhonenko, A; Thompson, CB; Yu, D | 1 |
Ravet, O | 1 |
Laties, AM; Liu, J; Lu, W; Mitchell, CH; Nguyen, J; Reigada, D | 1 |
Garralda Luquin, A | 1 |
Aréchiga-Figueroa, IA; Ferrer, T; López-Izquierdo, A; Ponce-Balbuena, D; Rodríguez-Menchaca, AA; Sánchez-Chapula, JA | 1 |
Hoffmann, GR; Laterza, AM; Sylvia, KE; Tartaglione, JP | 1 |
Flomenberg, N; Howell, A; Ko, YH; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pestell, RG; Sotgia, F | 1 |
Ann, DK; Chen, YR; Hu, S; Liu, X; Ma, H; Tsou, B; Yen, Y | 1 |
Abdulaziz, N; McCune, WJ; Shah, AR | 1 |
Beljanski, V; Nathanson, L; Noren, H; Rossi, F; Sarria, L; Schiller, PC | 1 |
Banga, R; Banga, V; Beljanski, V; Eltalla, A; Iyer, E; Kumrah, N; Naim, M; Nathanson, L; Parag, S; Shahin, L; Zacharias, B | 1 |
7 review(s) available for chloroquine and tamoxifen
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy.
Topics: Animals; Blindness; Chloroquine; Humans; Indomethacin; Oxidative Stress; Retina; Retinal Diseases; Tamoxifen; Thioridazine | 2004 |
[Drug-induced retinopathies].
Topics: Chloroquine; Humans; Phenothiazines; Piperazines; Purines; Retinal Diseases; Sildenafil Citrate; Sulfones; Tamoxifen; Vasodilator Agents | 2006 |
[Toxic effects of medications on the cornea].
Topics: Belgium; Chloroquine; Cornea; Corneal Diseases; Cytarabine; Drug-Related Side Effects and Adverse Reactions; Humans; Isotretinoin; Keratitis; Pharmaceutical Preparations; Rifabutin; Tamoxifen | 2007 |
[Ocular toxicity induced by medication].
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Estrogen Antagonists; Humans; Hydroxychloroquine; Tamoxifen | 2008 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Hydroxychloroquine; Mass Screening; Renal Insufficiency; Retinal Diseases; Retrospective Studies; Rheumatic Diseases; Risk Factors; Tamoxifen; Tomography, Optical Coherence | 2018 |
40 other study(ies) available for chloroquine and tamoxifen
Article | Year |
---|---|
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
Topics: Animals; Antimalarials; Bromobenzenes; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dioxanes; Gas Chromatography-Mass Spectrometry; Hepatitis B; HIV; Humans; Jamaica; Lactones; Leukemia P388; Lung Neoplasms; Mice; Molecular Structure; Mycobacterium tuberculosis; Neoplasms, Unknown Primary; Nuclear Magnetic Resonance, Biomolecular; Plasmodium berghei; Plasmodium falciparum; Porifera; Spectrometry, Mass, Electrospray Ionization; Tumor Cells, Cultured | 2001 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
Topics: Animals; Chagas Disease; DNA, Protozoan; Dose-Response Relationship, Drug; Glutathione; HeLa Cells; Humans; Imidazoles; Isoquinolines; Models, Molecular; Oxidation-Reduction; Quantitative Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51.
Topics: Antiprotozoal Agents; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibroblasts; Humans; Imidazoles; Molecular Docking Simulation; Molecular Structure; Parasitic Sensitivity Tests; Phenylethyl Alcohol; Structure-Activity Relationship; Trypanosoma cruzi | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Topics: Animals; Disease Models, Animal; Humans; Mice; Structure-Activity Relationship; Triazines; Tropolone; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2018 |
Potent Antimalarial 2-Pyrazolyl Quinolone
Topics: | 2018 |
Amino acid based prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
Topics: Amino Acids; Animals; Antimalarials; Antitubercular Agents; Cell Line; Female; Fosfomycin; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Plasmodium berghei; Plasmodium falciparum; Prodrugs | 2019 |
Phosphonodiamidate prodrugs of N-alkoxy analogs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
Topics: Antimalarials; Antitubercular Agents; Cell Line; Cell Survival; Fosfomycin; Humans; Hydroxamic Acids; Mycobacterium tuberculosis; Organophosphonates; Plasmodium falciparum; Prodrugs | 2019 |
Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
Topics: Antimalarials; Antitubercular Agents; Carbamates; Drug Evaluation, Preclinical; Fosfomycin; Humans; Inhibitory Concentration 50; Molecular Structure; Mycobacterium tuberculosis; Nitrofurans; Plasmodium falciparum; Prodrugs; Signal Transduction; Structure-Activity Relationship | 2019 |
Antiplasmodial Oleanane Triterpenoids from
Topics: Antimalarials; Guinea; Molecular Structure; Oleanolic Acid; Phytochemicals; Plant Bark; Plant Roots; Plasmodium falciparum; Terminalia | 2021 |
Corneal lipidosis in rats treated with amphiphilic cationic drugs.
Topics: Animals; Cations; Chloroquine; Chlorphentermine; Corneal Diseases; Female; Iprindole; Lipidoses; Male; Quinacrine; Rats; Rats, Inbred Strains; Tamoxifen | 1983 |
Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells?
Topics: Antineoplastic Agents; Chloroquine; Cholesterol; Drug Resistance; Humans; Kinetics; Liposomes; Membrane Fluidity; Neoplasms; Phosphatidylcholines; Tamoxifen | 1994 |
Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine.
Topics: Acetylglucosaminidase; Animals; Antimalarials; Cathepsin D; Cells, Cultured; Chloroquine; Drug Evaluation; Estrogen Antagonists; L-Lactate Dehydrogenase; Lysosomes; Pigment Epithelium of Eye; Swine; Tamoxifen | 1995 |
Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells.
Topics: Acetylglucosaminidase; Animals; Antimalarials; Cathepsin D; Cells, Cultured; Chloroquine; Estrogen Antagonists; Pigment Epithelium of Eye; Swine; Tamoxifen; Toremifene | 1998 |
A comparative study of the effect of pigment on drug toxicity in human choroidal melanocytes and retinal pigment epithelial cells.
Topics: Antimalarials; Antipsychotic Agents; Cell Survival; Chloroquine; Choroid; Estrogen Antagonists; Flow Cytometry; Humans; Melanins; Melanocytes; Monophenol Monooxygenase; Phagocytosis; Pigment Epithelium of Eye; Pigmentation; Pigments, Biological; Retina; Tamoxifen; Thioridazine; Ultraviolet Rays; Xenobiotics | 1999 |
The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures.
Topics: Animals; Cell Division; Cell Line; Cell Survival; Chloroquine; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Humans; Mitochondria; Phagocytosis; Pigment Epithelium of Eye; Rod Cell Outer Segment; Swine; Tamoxifen; Toremifene | 2001 |
Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Chloroquine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Ganciclovir; Gentamicins; Humans; Pigment Epithelium of Eye; Species Specificity; Swine; Tamoxifen; Toremifene | 2002 |
Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells.
Topics: Animals; Antimalarials; Cells, Cultured; Chloroquine; Estrogen Antagonists; Glutamic Acid; Humans; Pigment Epithelium of Eye; Swine; Tamoxifen; Toremifene | 2002 |
Toxicity of selected cationic drugs in retinoblastomal cultures and in cocultures of retinoblastomal and retinal pigment epithelial cell lines.
Topics: Cations; Cell Line; Cell Survival; Chloroquine; Coculture Techniques; Estrogen Receptor Modulators; Humans; Pigment Epithelium of Eye; Retinoblastoma; Tamoxifen; Toremifene | 2004 |
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Genes, myc; Genes, p53; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Tumor Suppressor Protein p53 | 2007 |
Restoration of lysosomal pH in RPE cells from cultured human and ABCA4(-/-) mice: pharmacologic approaches and functional recovery.
Topics: Animals; ATP-Binding Cassette Transporters; Cattle; Cells, Cultured; Chloroquine; Cyclic AMP; Humans; Hydrogen-Ion Concentration; Lysosomes; Mice; Mice, Inbred C57BL; Mice, Knockout; Photoreceptor Cells, Vertebrate; Pigment Epithelium of Eye; Receptor, Adenosine A2A; Receptors, Adrenergic, beta; Recovery of Function; Retinoids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2008 |
Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.
Topics: Animals; Cats; Cell Line; Chloroquine; Electrophysiology; Estrogen Antagonists; Heart Atria; Heart Ventricles; Humans; Ion Channel Gating; Ion Channels; Kinetics; Myocytes, Cardiac; Patch-Clamp Techniques; Phosphatidylinositol 4,5-Diphosphate; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Raloxifene Hydrochloride; Tamoxifen; Transfection | 2009 |
Potentiation of the mutagenicity and recombinagenicity of bleomycin in yeast by unconventional intercalating agents.
Topics: Amines; Animals; Benzophenones; Bleomycin; Cell Line; Chloroquine; Chlorpromazine; Cricetinae; DNA Damage; Drug Synergism; Gene Conversion; Intercalating Agents; Mefloquine; Mutagenicity Tests; Mutagens; Recombination, Genetic; Saccharomyces cerevisiae; Tamoxifen | 2011 |
Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Caveolin 1; Cell Communication; Cell Line, Tumor; Chloroquine; Coculture Techniques; Epithelial Cells; Fibroblasts; Glutamine; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Mitochondria; Neoplasms; Oxidative Phosphorylation; Phosphoric Monoester Hydrolases; Stromal Cells; Tamoxifen; Tumor Microenvironment | 2011 |
Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Hormonal; Apoptosis; Autophagy; Benzamides; Blotting, Western; Breast Neoplasms; Cell Proliferation; Chloroquine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tamoxifen; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Combination therapies enhance immunoregulatory properties of MIAMI cells.
Topics: Autophagy; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cell Proliferation; Chloroquine; Coculture Techniques; Gene Expression; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Interleukin-6; Leukocytes, Mononuclear; Lymphocyte Activation; Mesenchymal Stem Cells; MicroRNAs; Tamoxifen | 2019 |
Effects of autophagy modulators tamoxifen and chloroquine on the expression profiles of long non-coding RNAs in MIAMI cells exposed to IFNγ.
Topics: Autophagy; Chloroquine; Humans; Inflammation; Interferon-gamma; RNA, Long Noncoding; Tamoxifen | 2022 |